Market Minds Advisory
Postoperative Pain Market

Postoperative Pain Market: Opioid-Sparing Protocols Rewrite Surgical Recovery

Opioid crisis regulation and enhanced recovery protocols are pushing hospitals to replace opioid-first postoperative pain management with extended-release local anesthetics and regional nerve blocks, forcing manufacturers to prove non-opioid efficacy fast.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$8.9BMarket Size 2025
2036 FORECAST VALUE$22.5BBase Case , 2026 to 2036
CAGR 2026 TO 20368.8 %Bull 10.0% / Bear 7.5%
INCREMENTAL OPPORTUNITY$12.8BNet 10- year value creation
EXPANSION MULTIPLE2.32x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Postoperative pain management is moving decisively away from opioid-first protocols. Extended-release local anesthetics and regional nerve blocks are becoming the default first line, not the exception. That shift keeps accelerating. Surgeons who once treated opioids as the default now face real institutional pressure to justify that choice. Investors noticed too.
Extended-release local anesthetics grow fastest as hospitals adopt liposomal bupivacaine formulations that cover the highest-risk first days after surgery, followed closely by non-pharmacological pain devices offering genuinely opioid-free alternatives. North America holds the largest share on concentrated opioid crisis regulatory pressure and enhanced recovery protocol adoption. That regulatory pressure keeps intensifying as additional states tighten opioid prescribing limits. That regulatory pressure keeps compounding as additional payer quality metrics reward opioid-sparing protocols.
Competitive intensity concentrates among specialty pharmaceutical companies with proven extended-release formulations, while device manufacturers defend narrower, technically demanding positions in nerve block and neurostimulation technology. Hospital enhanced recovery after surgery committees are reshaping purchasing decisions, forcing manufacturers without documented opioid-sparing outcomes data to compete for a shrinking pool of opioid-tolerant procedures. Manufacturers without documented outcomes increasingly find themselves excluded from serious formulary conversations entirely.
Market Definition
The postoperative pain market covers pharmaceutical and device-based products used to manage pain following surgical procedures, including extended-release local anesthetics, regional nerve block anesthesia, patient-controlled analgesia devices, non-opioid oral and intravenous analgesics, opioid analgesics, and non-pharmacological pain management devices. It excludes chronic pain management products not tied to a surgical procedure, general anesthesia products used during surgery itself, and non-clinical pain relief products such as over-the-counter topical analgesics.
Base Year Value
$8.9B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.8% base case. Bull 10.0%. Bear 7.5%.
Fastest Growth Segment
Extended-Release Local Anesthetics: 14.2% CAGR
Fastest Growth Country
China: 12.5% CAGR
Fastest Growth Region
South Asia and Pacific: 10.8% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
Pacira BioSciences Inc., Avanos Medical Inc., B. Braun Melsungen AG, Baxter International Inc., Pfizer Inc. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Postoperative Pain Market Forecast Scenarios

postoperative-pain-market-size-forecast-scenario-1787307810463
Between 2020 and 2025 the market grew at roughly 7.5% a year, accelerating as opioid prescribing restrictions tightened across an expanding number of states and hospital enhanced recovery after surgery committees began mandating multimodal, opioid-sparing protocols as standard practice. That acceleration caught several opioid-focused manufacturers unprepared for the pace of protocol change. That scramble caught many hospitals unprepared.
The base case carries the market to an 8.8% CAGR on three mechanisms. First, opioid crisis regulation keeps tightening prescribing limits, forcing hospitals toward non-opioid alternatives on compliance rather than purely clinical timelines. Second, rising global surgical volume keeps expanding the total addressable postoperative pain market independent of any single protocol shift. Third, enhanced recovery after surgery protocols keep standardizing multimodal pain management that combines extended-release local anesthetics with reduced opioid reliance. These three mechanisms reinforce each other steadily across most major surgical markets.
The bull case reaches 10.0% if additional jurisdictions adopt binding opioid prescribing limits faster than currently scheduled, accelerating protocol conversion industry-wide. The bear case falls to 7.5% if extended-release local anesthetic cost premiums meaningfully slow hospital formulary adoption relative to the pace clinical guidelines actually recommend. That divergence rests largely on hospital budget constraints. Budget cycles matter most.

Opioid-Sparing Protocols Are Setting the Category's Growth Pace

Three forces converge on this market at once. Opioid crisis regulation keeps tightening prescribing limits on fixed compliance timelines, rising surgical volume keeps expanding the total addressable market, and enhanced recovery protocols keep standardizing multimodal pain management. Manufacturers unable to document opioid-sparing outcomes risk losing hospital formulary access to competitors who invested in clinical evidence earlier. Manufacturers unable to prove opioid-sparing outcomes increas
MARKET CONCENTRATION (CR5)42%Top five manufacturers hold well under half share
AVERAGE TREATMENT COST$285/procedureExtended-release formulations command a premium over generic opioids
TOP PRODUCING COUNTRY SHARE28%United States leads installed extended-release manufacturing capacity currently
HOSPITAL FORMULARY ADOPTION64%Major hospital systems have adopted opioid-sparing protocols formally
TRADE INTENSITY19%Most product volume manufactures close to major surgical markets
ACTIVE INGREDIENT COST SHARE34% of COGSBupivacaine and lipid encapsulation inputs dominate production cost
Commercially, the market splits between standard opioid and generic non-opioid analgesics, priced competitively and sold largely on cost against decades-old alternatives, and extended-release local anesthetics and device-based options, priced at meaningful premium and sold on documented opioid-sparing outcomes hospitals need for enhanced recovery protocol compliance. That premium category commands disproportionate growth relative to its unit volume share of the overall market. That margin gap widens as hospitals demand documented clinical evidence readiness.
Over the next decade the defining question is whether extended-release and device-based alternatives fully displace opioids across most elective surgical procedures, or whether cost and reimbursement limitations keep opioid-sparing protocols concentrated in the highest-risk procedures rather than becoming the universal default for postoperative pain management everywhere. Hospital budget constraints will likely determine which outcome prevails.
"Ten years ago a surgeon writing a postoperative opioid prescription was just routine paperwork. Now that same surgeon has to document why they didn't use a non-opioid alternative first, and that single documentation burden has quietly rewritten which products actually get considered for hospital formularies today."
Director, Pain Management and Surgical Devices Practice · MMA Healthcare / Pain

Market Trends

Liposomal Bupivacaine Displaces Opioid-First Postoperative Protocols

Extended-release liposomal bupivacaine formulations, which deliver local anesthesia coverage across the highest-risk first several days after surgery rather than the few hours conventional local anesthetics provide, have moved from a specialty option to a standard formulary inclusion at an expanding number of major hospital systems tracked through formulary adoption surveys. Pacira BioSciences and Avanos Medical have both expanded extended-release manufacturing capacity specifically targeting this formulary conversion wave. Manufacturers without extended-release formulations increasingly lose formulary consideration to competitors already delivering documented multi-day coverage reliably. That formulary momentum increasingly determines which manufacturers win the largest hospital system contracts.
Market Impact: Adds 5 to 9 limits yearly

Enhanced Recovery Protocols Standardize Multimodal Pain Management

Hospital enhanced recovery after surgery committees increasingly mandate multimodal pain management protocols combining extended-release local anesthetics, regional nerve blocks, and non-opioid oral analgesics as the default approach rather than opioid-first prescribing, a shift documented across an expanding number of surgical specialty guidelines. B. Braun and Baxter have both expanded regional nerve block product lines specifically targeting hospitals implementing these standardized protocols. Hospitals increasingly evaluate pain management suppliers on documented protocol compatibility alongside pure clinical efficacy, giving multimodal-capable manufacturers a genuine advantage. That protocol compatibility increasingly shapes which manufacturers win the largest multi-year hospital contracts.
Market Impact: Adds 3% to 5% procedures yearly

Market Opportunities and Growth Drivers

Opioid Crisis Regulation Pushes Hospitals Toward Non-Opioid Protocols

Opioid prescribing regulation, tracked across an expanding list of state and national jurisdictions setting binding limits on postoperative opioid quantities and duration, creates genuinely fixed-timeline demand for non-opioid alternatives that hospitals cannot indefinitely defer the way voluntary clinical guideline adoption often gets deprioritized during budget pressure. Each newly enacted prescribing limit represents recurring, multi-year conversion demand tied directly to that jurisdiction's surgical volume, giving non-opioid manufacturers a regulatory-anchored growth driver considerably more predictable than categories dependent purely on voluntary clinical adoption alone. That regulatory anchor gives manufacturers unusually reliable multi-year demand visibility.
Market Impact: Limits adoption to 45-60% of proced

Rising Surgical Volume Expands the Addressable Market

Global surgical procedure volume keeps expanding as aging populations and improving healthcare access drive continued growth in elective and emergency surgery rates, tracked by national health statistics agencies, creating durable underlying demand for postoperative pain management independent of any single protocol shift toward non-opioid alternatives. Each additional surgical procedure represents recurring demand for some form of postoperative pain management regardless of which specific product category ultimately captures that procedure. That underlying volume growth gives manufacturers unusually reliable long-term capacity planning visibility across the category broadly. That underlying demand persists regardless of which specific protocol ultimately wins.
Market Impact: Limits access to 35-50% of hospital

Market Restraints and Challenges

Extended-Release Formulations Carry Significant Cost Premium

Extended-release local anesthetic formulations carry a substantial cost premium over generic opioid and conventional local anesthetic alternatives, and the root cause is that liposomal encapsulation manufacturing requires meaningfully more complex production processes than conventional drug formulation techniques developed decades ago. This cost premium creates genuine adoption barriers for hospitals and health systems operating under tight per-procedure budget constraints, particularly outside the highest-risk procedures where the clinical benefit most clearly justifies the added expense. Manufacturers are mitigating the barrier through outcomes-based pricing agreements and reduced-cost formulations targeting broader procedure eligibility specifically.
Market Impact: Covers 60+ procedure types

Regional Nerve Blocks Require Specialized Anesthesiologist Training

Regional nerve block techniques, while clinically effective for opioid-sparing pain management, require specialized anesthesiologist training and ultrasound guidance skill that many hospitals, particularly smaller and rural facilities, do not currently have on staff in sufficient numbers, and the root cause is that nerve block technique training has historically been a specialized subspecialty rather than standard anesthesiology curriculum. This skill gap limits nerve block adoption outside major academic medical centers with dedicated regional anesthesia programs. Manufacturers are mitigating the gap through simplified ultrasound-guided kits and structured training programs targeting community hospital anesthesiologists specifically.
Market Impact: Reduces opioid use 40% to 55%
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows product technology and mechanism of action, a single classification logic distinguishing pharmacological and device-based approaches to postoperative pain. Surgical specialty and site of care are treated as separate commercial dimensions, not parallel segments here. Clinical evidence requirements and reimbursement complexity vary meaningfully across these categories, shaping which manufacturers can credibly compete for each application.
postoperative-pain-market-market-share-analysis-1787307810997

Extended-Release Local Anesthetics

Extended-release local anesthetics grow fastest at 14.2%, about 1.61 times the overall rate, as hospitals increasingly adopt liposomal bupivacaine and similar formulations covering the highest-risk first several days after surgery, replacing opioid-first prescribing on enhanced recovery protocol timelines. These formulations command substantial premium pricing over conventional local anesthetics that reflects genuine manufacturing complexity and the opioid-sparing outcomes value hospitals pay for directly. Pacira BioSciences leads commercial capacity expansion, having invested heavily in liposomal encapsulation production lines since 2023 specifically targeting this formulary conversion. Adoption is fastest among academic medical centers with dedicated enhanced recovery programs, while community hospital adoption continues growing more gradually alongside broader clinical guideline dissemination. That evidence dependency increasingly determines which manufacturers win the largest formulary contracts.
CAGR 14.2%

Non-Pharmacological Pain Management Devices

Non-pharmacological pain management devices, including neurostimulation and cryoanalgesia systems that provide genuinely opioid-free pain relief, grow at 13.5%, the second-fastest category, as hospitals seek alternatives entirely outside pharmaceutical opioid exposure risk for appropriate procedure types. This category commands meaningful premium pricing over standard analgesics, reflecting genuine device engineering complexity and the zero-opioid-exposure value hospitals specifically pay for. Avanos Medical maintains a substantial non-pharmacological device product line serving both orthopedic and general surgery customers directly. Growth here reflects genuine technology-driven expansion within pain management rather than pure substitution from adjacent pharmaceutical categories. Manufacturers without proven device reliability data increasingly struggle to win multi-year hospital contracts against pharmaceutical incumbents with longer clinical track records.
CAGR 13.5%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads on concentrated opioid crisis regulatory pressure and enhanced recovery protocol adoption, Western Europe follows on established multimodal pain management infrastructure, and East Asia grows fastest among major regions. Latin America and the Middle East grow steadily off smaller current bases, while Eastern Europe trails the regional average.

North America

The United States hosts the world's largest concentration of opioid prescribing regulation, with an expanding number of states enacting binding postoperative opioid limits that have already reshaped hospital formulary decisions at major health systems across the country substantially. Pacira BioSciences and Avanos Medical both run substantial domestic manufacturing capacity, serving academic medical centers, community hospitals, and ambulatory surgical centers from facilities across the country. Canada's federal opioid strategy follows a broadly similar regulatory trajectory, though generally trailing the pace of individual American state legislation. Growth trails East Asia because the region's enhanced recovery protocol adoption is already extensively built out, leaving formulary depth rather than initial protocol adoption as the primary driver going forward.
Share: 31% | CAGR: 9.2% (2026 to 2036)

Western Europe

The United Kingdom's National Health Service has driven comprehensive enhanced recovery after surgery protocol adoption across its hospital network, with standardized multimodal pain management guidelines already reshaping procurement decisions at major surgical centers throughout the country. Germany and France both maintain well-developed regional anesthesia training infrastructure, with B. Braun's substantial European operations anchoring regional nerve block product supply serving both domestic and export markets across the continent. The European Medicines Agency's regulatory framework has supported extended-release formulation approval broadly across member states. Growth trails East Asia as the region's protocol adoption is already substantially mature relative to faster-growing emerging surgical markets. That regulatory clarity increasingly guides formulary decisions in other developing surgical markets too.
Share: 24% | CAGR: 7.3% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
postoperative-pain-market-country-cagr-analysis-1787307811522

Where Pain Management Manufacturers Can Defend Margin

Four commercial moves separate manufacturers capturing durable opioid-sparing growth from those competing purely on commodity generic pricing: clinical evidence investment timing, formulation cost reduction, hospital partnership depth, and training infrastructure diversification. Each move converts a technical or timing advantage into a defensible commercial position competitors without matching clinical evidence or training depth cannot easily replicate quickly.

Invest in Outcomes Data Ahead of Formulary Review Cycles

Hospitals facing enhanced recovery protocol mandates need manufacturers who can actually document opioid-sparing outcomes data, and manufacturers investing in clinical evidence generation ahead of confirmed formulary review cycles capture disproportionate share of protocol conversion as hospitals lock in supplier relationships well before competitors can match documented evidence. This is a genuine evidence race, and manufacturers who wait for demand to fully materialize before investing risk losing formulary access to competitors already documented and ready. Manufacturers with secured outcomes data typically capture 35% to 50% of the resulting formulary conversion volume before competitors achieve comparable evidence.
Market Impact: Early movers capture 35% to 50% of

Develop Reduced-Cost Formulations to Close Adoption Gaps

Extended-release formulation cost premiums represent a genuine barrier to broader hospital adoption outside the highest-risk procedures, and manufacturers investing in reduced-cost formulation technology that closes this gap while preserving multi-day coverage capture applications competitors without comparable cost engineering cannot serve. This engineering investment differentiates beyond pure clinical efficacy competition, addressing the specific budget objection that otherwise limits addressable procedure eligibility meaningfully. Manufacturers with proven cost-reduced formulations report expanding their addressable procedure range by 20% to 30% relative to competitors without comparable capability. Manufacturers without such formulations increasingly lose formulary bids to better-positioned competitors.
Market Impact: Expands addressable procedures by 2

Build Deep Hospital Partnership Relationships for Protocol Adoption

Hospital enhanced recovery committees pursuing standardized multimodal protocols increasingly seek manufacturer partners who can support broader clinical education and protocol design conversations rather than pure transactional product supply, and manufacturers building this deeper partnership capability capture premium protocol-anchored business that transactional competitors cannot access as easily. This partnership approach also builds switching costs, since a hospital's protocol design and staff training often becomes tied to the specific manufacturer relationship over time. Manufacturers building this partnership depth report commanding 18% to 28% pricing premiums over competitors offering purely transactional supply relationships.
Market Impact: Commands 18% to 28% premium for par

Diversify Training Infrastructure to Reach Community Hospitals

Regional nerve block and device adoption depends heavily on specialized clinician training that most community and rural hospitals lack, and manufacturers building diversified training infrastructure including simplified kits and remote training programs capture community hospital accounts competitors dependent on academic medical center relationships alone cannot reach. Manufacturers pursuing diversified training infrastructure report expanding market reach by 22% to 32% into community hospital settings relative to competitors dependent on academic center relationships alone. That expanded reach compounds meaningfully as community hospitals increasingly adopt enhanced recovery protocols requiring documented training partnerships further.
Market Impact: Expands community hospital reach by

Who Controls the Margin Pool

Concentration sits at a moderate CR5 of 42%, with a gap separating specialty pharmaceutical companies with proven extended-release formulations from device manufacturers defending narrower nerve block and neurostimulation positions. Pacira BioSciences and Avanos Medical compete on formulary breadth and clinical evidence depth, while B. Braun and Baxter anchor strong positions in regional anesthesia and infusion device innovation respectively. Numerous smaller generic manufacturers compete on pri
Current competitive activity runs along three lines: clinical evidence generation, where manufacturers race to document opioid-sparing outcomes ahead of formulary review cycles; formulation cost reduction, increasingly central to closing adoption gaps outside highest-risk procedures; and hospital partnership building, as manufacturers compete for protocol-anchored, higher-margin business. All participants are assessed on one consistent basis, annual revenue from postoperative pain management products.

Pressure is building from two directions. Manufacturers with strong clinical evidence and formulary relationships are capturing disproportionate protocol-driven share, a dynamic slower-moving competitors cannot easily counter through pricing alone. Meanwhile generic manufacturers are scaling both price-competitive and increasingly technically capable production, pressuring branded incumbents in cost-sensitive standard analgesic segments. Rankings over the next five years will shift toward manufacturers combining clinical evidence speed with genuine training infrastructure depth.
postoperative-pain-market-company-positioning-matrix-1787307812046

Competitive Moat and Risk Dimensions

PACIRA BIOSCIENCES INC.

Moat: Deepest liposomal formulation expertise

Pacira's pioneering liposomal bupivacaine platform and extensive clinical outcomes data, accumulated over more than a decade of hospital deployment, give it a defensible position in the fastest-growing extended-release category that funds expansion into adjacent formulation and delivery technology few narrower competitors can match. That evidence advantage compounds as hospitals increasingly demand documented outcomes before formulary inclusion.
PACIRA BIOSCIENCES INC.

Risk: Narrow extended-release category concentration

Pacira's revenue concentration in extended-release local anesthetics, while highly defensible, leaves it more exposed than diversified competitors to any sustained shift in formulation technology or alternative pain management approach adoption within that specific narrow category over the coming decade. That narrow exposure could meaningfully slow Pacira's growth if a competing formulation technology gains faster hospital traction.
AVANOS MEDICAL INC.

Moat: Broadest device and pharmaceutical portfolio

Avanos Medical's product breadth spanning both non-pharmacological devices and pharmaceutical delivery systems lets it serve hospital enhanced recovery committees as a single-vendor relationship few narrower competitors can match, particularly valuable as hospitals increasingly consolidate pain management vendor relationships. That relationship breadth compounds as hospitals prefer fewer, more capable pain management vendor partnerships overall.
AVANOS MEDICAL INC.

Risk: Device reimbursement policy exposure

Avanos Medical's non-pharmacological device revenue depends meaningfully on favorable reimbursement policy that regulators could revise, exposing a share of its device business to policy risk its pharmaceutical delivery business does not face to the same degree. That policy exposure could meaningfully compress margin if reimbursement rates decline faster than device cost efficiency improves.

Players Tracked

Prominent Players

Pacira BioSciences Inc.
Avanos Medical Inc.
B. Braun Melsungen AG
Baxter International Inc.
Pfizer Inc.

Other Key Players

Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
Mallinckrodt Pharmaceuticals
Endo International plc
Heron Therapeutics Inc.
Nevro Corp.
Medtronic plc
Boston Scientific Corporation
Smiths Medical
ICU Medical Inc.
Cook Medical
Halozyme Therapeutics Inc.
Recro Pharma Inc.
Grunenthal Group

Recent Developments

MARCH 2025

Pacira BioSciences expands liposomal manufacturing capacity

Pacira BioSciences commissioned expanded liposomal bupivacaine manufacturing capacity specifically targeting hospital systems transitioning to enhanced recovery after surgery protocols nationwide. This was an organic capacity expansion funded from existing capital, not an acquisition or partnership, reflecting sustained demand growth from hospitals seeking documented opioid-sparing alternatives.
Signal: Continued capacity investment in liposomal
SEPTEMBER 2024

Avanos Medical signs supply agreement with major hospital network

Avanos Medical signed a multi-year supply agreement with a major hospital network to provide regional nerve block kits and non-pharmacological devices across its enhanced recovery protocol implementation. This was a commercial supply agreement, not a joint venture or acquisition, securing recurring volume across the network's facilities.
Signal: Large hospital network contracts show heal
JANUARY 2025

B. Braun acquires regional anesthesia training technology start-up

B. Braun completed the acquisition of a privately held company developing simplified ultrasound-guided nerve block training technology for community hospital anesthesiologists. This was an acquisition, not a joint venture or minority investment, giving B. Braun full ownership and control of the acquired technology and development team.
Signal: Continued acquisition activity in training

Active Pharmaceutical Ingredients Drive Production Cost

Bupivacaine active ingredient and lipid encapsulation materials together account for roughly thirty-four percent of production COGS, sourced from a mix of active pharmaceutical ingredient manufacturers concentrated in North America, Western Europe, and increasingly India, where pharmaceutical manufacturing capacity has expanded steadily since 2020. Cold-chain storage and specialized packaging requirements add a further meaningful cost layer for liposomal formulations specifically.
The clearest recent volatility event traces to 2021 and 2022, when global active pharmaceutical ingredient supply chains experienced significant disruption as manufacturing shutdowns in several major producing regions, documented by the FDA's drug shortage reporting system, tightened established ingredient supply chains industry-wide. Several manufacturers reported meaningful cost pass-through delays during this period, as fixed-price hospital contracts limited their ability to immediately adjust pricing to reflect rapidly changing ingredient costs.

Exposure varies by manufacturer scale and sourcing relationships. Larger manufacturers with direct, long-term ingredient supply agreements and diversified sourcing across multiple regions weathered the volatility with meaningfully less disruption than smaller manufacturers dependent on spot market purchasing. Manufacturers serving hospital accounts under fixed multi-year contracts faced particular pressure to maintain pricing commitments despite raw material cost increases across the category.
postoperative-pain-market-cost-volatility-analysis-1787307812243

Diversify Active Ingredient Sourcing Across Regions

Manufacturers are increasingly qualifying multiple active pharmaceutical ingredient sourcing regions, reducing exposure to any one region's manufacturing disruption or export policy shift affecting a concentrated ingredient supply base. This diversification approach increasingly mirrors sourcing discipline already standard across other pharmaceutical manufacturing categories facing comparable supply concentration risk. Manufacturers without such diversification increasingly face higher cost volatility exposure.

Index Long-Term Hospital Contracts to Ingredient Price Benchmarks

More manufacturers now write ingredient price pass-through clauses directly into multi-year hospital supply agreements, tying product pricing to published pharmaceutical ingredient benchmark indices rather than negotiating each adjustment separately after cost increases have already occurred. Hospitals generally accept these clauses now, having watched competitors absorb painful losses without comparable protection previously. That protection now shapes vendor selection.

Invest in Manufacturing Efficiency to Reduce Ingredient Waste

Some manufacturers are optimizing liposomal encapsulation yield and batch efficiency to reduce active ingredient volume required per unit while maintaining formulation stability and coverage duration, cutting raw material exposure per unit even as optimization requires meaningful upfront process engineering investment. That efficiency gain increasingly favors manufacturers with strong process engineering expertise over those relying on standard batch protocols.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with real margin separation. Standard opioid and generic non-opioid analgesics compete largely on price against decades-old alternatives, earning modest margins defended through production scale. Extended-release and device-based options earn substantially more because hospitals pay for documented opioid-sparing outcomes conventional analgesics alone cannot deliver. That gap widens as hospitals demand outcomes data before committing formulary budget. Manufac
The tension between standard analgesic volume and premium extended-release positioning shapes manufacturer strategy directly: standard analgesics keep production lines running and build broad hospital relationships, but manufacturers that let standard volume crowd out extended-release and device investment risk losing the fastest-growing, highest-margin category to more capability-focused competitors. Manufacturers that manage this balance well capture both broad hospital presence and premium margin.

High-value pools concentrate in extended-release local anesthetics and non-pharmacological devices, where opioid-sparing outcomes value and regulatory compliance justify premium economics few commodity-focused competitors can match. The emerging reduced-cost formulation tier currently earns unevenly as manufacturers absorb engineering cost against still-developing commercial adoption. That unevenness should ease as formulations mature and gain broader hospital validation.

Volume / Commodity-Adjacent Tier

Standard opioid and generic non-opioid analgesics sold on price against decades-old alternatives to mainstream surgical procedures, where production scale determines acceptable margin. Production scale and manufacturing efficiency together determine which manufacturers sustain acceptable margin here.
Gross Margin: 12-24%

Premium / Certified Tier

Extended-release local anesthetics and device-based options commanding premium pricing from hospitals prioritizing documented opioid-sparing outcomes, who pay durable premiums for evidence rather than risk protocol noncompliance. Evidence-driven hospitals pay these premiums without hesitation given protocol compliance risk.
Gross Margin: 38-52%

Sustainability / Regulatory / Next-Generation Tier

Reduced-cost formulations and next-generation delivery technology still absorbing engineering investment against developing commercial adoption, where manufacturers are betting research capital on technology they expect hospitals to demand broadly within several years.
Gross Margin: 15-45%
postoperative-pain-market-portfolio-architecture-1787307812747

High-value Sub-segments and Strategic Watch-out

Protocol-Mandated Extended-Release Anesthetics

High value and high growth as enhanced recovery protocols expand across hospital systems, commanding durable premium pricing once formulary decisions force evidence-based sourcing industry-wide. Manufacturers with the strongest outcomes data increasingly win formulary slots competitors slower to invest simply cannot secure. That gap widens further each additional quarter.
Gross Margin: 40-52%

Community Hospital Nerve Block Adoption

High value with strong current growth as simplified training and kits expand device reach, priced above standard analgesics while remaining accessible to community hospital budgets. Adoption is broadening steadily beyond academic centers into mainstream community hospital settings seeking comparable outcomes. Momentum keeps building steadily each budget cycle.
Gross Margin: 30-42%

Standard Opioid and Generic Analgesics

The volume core, sold on price to mainstream surgical procedures, defended mainly through production scale and thin per-unit margin discipline across facilities. Competitive pressure here concentrates on production efficiency and cost rather than the opioid-sparing differentiation reshaping premium tiers overall today. overall consistently here today.
Gross Margin: 12-24%

Opioid-Dependent Legacy Protocols

The strategic watch-out, facing mounting regulatory pressure as opioid-sparing alternatives increasingly become the standard expectation across surgical specialties. Manufacturers still dependent on this declining tier should be actively redirecting investment toward opioid-sparing alternatives rather than defending protocols facing rising compliance and reimbursement risk. steadily overall.
Gross Margin: 6-18%

How Postoperative Pain Demand Actually Recurs

Demand here runs on continuous consumption tied directly to hospital surgical procedure volume rather than discrete purchase events. A hospital that adopts a manufacturer's extended-release formulation into its formulary consumes matched product with every eligible procedure, making a single formulary decision worth years of recurring volume rather than a standalone transaction. That recurring pattern gives manufacturers unusually predictable, multi-year revenue visibility once a formulary decis
Adoption depth varies sharply by facility type. Academic medical centers with dedicated enhanced recovery programs integrate extended-release and device protocols deeply into standardized surgical pathways once adopted, making supplier switching costly and rare absent a compelling clinical or cost reason. Community and rural hospitals, by contrast, evaluate suppliers more flexibly as training and infrastructure constraints limit adoption depth, creating more frequent switching opportunities between competing manufacturers.

Buyer profiles are shifting generationally as younger anesthesiologists and surgeons, trained on multimodal, opioid-sparing protocols during residency, increasingly treat extended-release and device-based options as the default choice rather than an alternative requiring special justification. Older clinicians trained primarily on opioid-first protocols are adapting more gradually, but that generational shift is accelerating as regulatory deadlines force protocol decisions across the industry broadly.
postoperative-pain-market-end-use-penetration-index-1787307813238

Where Postoperative Pain Value Concentrates Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CLINICAL EVIDENCE INVESTMENT

Build outcomes data ahead of confirmed formulary review cycles

Hospitals facing enhanced recovery protocol mandates need manufacturers ready to document opioid-sparing outcomes on schedule, and manufacturers investing ahead of confirmed formulary review cycles capture the conversion wave before competitors catch up. This is a genuine evidence race with real consequences for companies that wait too long to commit clinical trial capital. Manufacturers moving decisively now will own the formulary relationships that regulatory deadlines are about to make urgently valuable across an expanding list of jurisdictions., a race with real consequences for hesitant manufacturers.
02 / FORMULATION COST REDUCTION

Close the adoption gap before it becomes a category ceiling

Extended-release cost premiums genuinely cap addressable procedure range for manufacturers without cost-reduced formulations, and manufacturers investing in engineering that closes this gap capture procedures competitors cannot serve credibly. This engineering investment differentiates beyond pure clinical efficacy competition. Companies treating cost reduction as secondary to clinical evidence generation are underestimating how directly it determines total addressable procedure volume as hospital budgets tighten further., and that ceiling grows more consequential each year as hospital budgets tighten and procedure eligibility expands across more surgical categories.
03 / HOSPITAL PARTNERSHIP DEVELOPMENT

Build partnerships beyond transactional product supply

Hospital enhanced recovery committees pursuing standardized protocols increasingly seek manufacturer partners for broader clinical education conversations, not pure transactional supply, and manufacturers building this deeper capability capture premium protocol-anchored business transactional competitors cannot access. This partnership approach also builds genuine switching costs over time. Companies still selling purely on price and specification sheets are missing the relationship depth that increasingly determines premium account retention long-term., and that gap only widens as hospitals increasingly demand deeper clinical education and protocol partnership commitment over multi-year cycles.
04 / TRAINING INFRASTRUCTURE DIVERSIFICATION

Reach community hospitals before academic centers saturate

Regional nerve block and device adoption is a persistent function of clinician training availability outside manufacturer control at any single facility, and manufacturers dependent on academic center relationships alone remain exposed to slower growth once those markets mature and saturate. Diversifying training infrastructure now, rather than reactively after academic center growth slows, protects volume durably. This is a strategic priority every manufacturer serving hospital accounts should treat as a genuine growth lever, not an afterthought investment., a growth lever most competitors still treat as an afterthought.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Postoperative Pain Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Postoperative Pain Exposure Evaluation 2025-26
CLIENT PROFILE
A regional hospital network operating six surgical facilities across three states approached MMA while planning a network-wide transition to enhanced recovery after surgery protocols ahead of a payer-driven quality reporting deadline. The client reported roughly USD 11.5 million in annual postoperative pain management spending across its network, with fragmented opioid-first practices varying by facility (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Management needed to standardize pain management protocols across all six facilities while managing the cost increase extended-release and device options represented over generic opioids, without disrupting existing surgical scheduling or clinician workflows. The board wanted a defensible protocol standardization plan before the payer reporting deadline arrived. Clinical leadership also needed buy-in from each facility's chief of surgery before implementation could begin.
MMA APPROACH
MMA benchmarked clinical outcomes data and training requirements across five qualified manufacturers against the network's specific procedure mix and deadline, modeled total cost of transition including the price differential versus generic opioids, and assessed each manufacturer's track record delivering comparable-scale protocol implementations for other hospital networks. We also interviewed the network's anesthesiology leadership to confirm real-world training constraints the model could not capture.
KEY FINDINGS
  1. Only two of five benchmarked manufacturers could credibly commit to supporting network-wide protocol standardization within the payer reporting deadline given current training capacity.
  2. The cost differential versus generic opioids was meaningfully lower than the client's initial internal estimate once volume-based pricing was properly negotiated against a multi-year commitment.
  3. One manufacturer's prior experience standardizing protocols at a comparably sized hospital network provided a proven training rollout playbook that reduced projected disruption risk considerably.
  4. Sequencing the rollout by facility rather than attempting a single simultaneous network-wide changeover reduced clinical disruption risk while still meeting the reporting deadline comfortably (client-reported, unverified by MMA).
CLIENT PROFILE
A regional hospital network operating six surgical facilities across three states approached MMA while planning a network-wide transition to enhanced recovery after surgery protocols ahead of a payer-driven quality reporting deadline. The client reported roughly USD 11.5 million in annual postoperative pain management spending across its network, with fragmented opioid-first practices varying by facility (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Management needed to standardize pain management protocols across all six facilities while managing the cost increase extended-release and device options represented over generic opioids, without disrupting existing surgical scheduling or clinician workflows. The board wanted a defensible protocol standardization plan before the payer reporting deadline arrived. Clinical leadership also needed buy-in from each facility's chief of surgery before implementation could begin.
MMA APPROACH
MMA benchmarked clinical outcomes data and training requirements across five qualified manufacturers against the network's specific procedure mix and deadline, modeled total cost of transition including the price differential versus generic opioids, and assessed each manufacturer's track record delivering comparable-scale protocol implementations for other hospital networks. We also interviewed the network's anesthesiology leadership to confirm real-world training constraints the model could not capture.
KEY FINDINGS
  1. Only two of five benchmarked manufacturers could credibly commit to supporting network-wide protocol standardization within the payer reporting deadline given current training capacity.
  2. The cost differential versus generic opioids was meaningfully lower than the client's initial internal estimate once volume-based pricing was properly negotiated against a multi-year commitment.
  3. One manufacturer's prior experience standardizing protocols at a comparably sized hospital network provided a proven training rollout playbook that reduced projected disruption risk considerably.
  4. Sequencing the rollout by facility rather than attempting a single simultaneous network-wide changeover reduced clinical disruption risk while still meeting the reporting deadline comfortably (client-reported, unverified by MMA).
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 3 months): Finalize the supply and training agreement with the selected manufacturer and begin facility-by-facility rollout planning. Phase 2: Phase 2 (3 to 8 months): Execute the phased facility rollout, prioritizing the facility with the earliest payer reporting deadline. Phase 3: Phase 3 (8 to 14 months): Complete rollout across all remaining facilities and evaluate outcomes against the original opioid-first benchmark.
OUTCOME
The hospital network began Phase 1 implementation on schedule, reporting that the negotiated volume pricing kept the total transition cost within the client's original approved budget. The network also reported measurable reductions in postoperative opioid prescribing following the rollout (client-reported, unverified by MMA). reflecting stronger clinical confidence overall.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Postoperative Pain Market?

The postoperative pain market was valued at USD 8.9 billion in 2025. Growth is driven by opioid crisis regulation, rising surgical volume, and enhanced recovery after surgery protocol adoption.

How large will the Postoperative Pain Market be by 2036?

The market is projected to reach USD 22.49 billion by 2036 under the base case scenario. That reflects an expansion multiple of roughly 2.32 times the 2026 value.

What is the CAGR for the Postoperative Pain Market 2026 to 2036?

The base case CAGR is 8.8%, with a bull case of 10.0% and a bear case of 7.5%. Opioid prescribing regulation speed and hospital budget constraints are the main swing factors.

Which segment is growing fastest?

Extended-release local anesthetics grow fastest at 14.2% CAGR, roughly 1.61 times the overall market rate. Non-pharmacological pain management devices follow as the second-fastest segment at 13.5%.

Who are the major companies in the Postoperative Pain Market?

Leading manufacturers include Pacira BioSciences, Avanos Medical, Braun Melsungen, Baxter International, and Pfizer, together holding a combined 42% share of the market. This reflects a consistent revenue basis across all five companies.

Which country is growing fastest?

China is the fastest-growing country at 12.5% CAGR, driven by rapidly expanding surgical volume and spreading enhanced recovery protocol adoption. Domestic hospital networks anchor much of that growth.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product Technology and Mechanism

  • Extended-Release Local Anesthetics
  • Regional Nerve Block Anesthesia
  • Patient-Controlled Analgesia Pumps and Devices
  • Non-Opioid Oral and IV Analgesics
  • Opioid Analgesics
  • Non-Pharmacological Pain Management Devices

By End-Use Industry

  • Academic Medical Centers
  • Community Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic and Sports Medicine Surgery
  • General and Abdominal Surgery

By Commercial Dimension

  • Direct Hospital System Supply
  • Group Purchasing Organization Contracts
  • Distributor and Wholesale Channel
  • Ambulatory Surgical Center Supply

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The postoperative pain market comprises pharmaceutical and device-based products used to manage pain following surgical procedures, including extended-release local anesthetics, regional nerve block anesthesia, patient-controlled analgesia devices, non-opioid oral and intravenous analgesics, opioid analgesics, and non-pharmacological pain management devices. Chronic pain management products not tied to a surgical procedure, general anesthesia products used during surgery itself, and non-clinical pain relief products such as over-the-counter topical analgesics are excluded.
Quantitative Units
USD billions (current prices); procedure volume where applicable
Segmentation Dimensions
By Product Technology and Mechanism; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Pacira BioSciences Inc., Avanos Medical Inc., B. Braun Melsungen AG, Baxter International Inc., Pfizer Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG, Mallinckrodt Pharmaceuticals, Endo International plc, Heron Therapeutics Inc., Nevro Corp., Medtronic plc, Boston Scientific Corporation, Smiths Medical, ICU Medical Inc., Cook Medical, Halozyme Therapeutics Inc., Recro Pharma Inc., Grunenthal Group
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-802
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Postoperative Pain Market Report (2026 to 2036).

The full MMA Postoperative Pain Market report sizes demand across six product technology and mechanism categories, five end-use settings, four commercial dimensions, and seven regions through 2036. It profiles twenty companies on a consistent revenue basis, scoring each on clinical evidence depth, formulation cost position, and hospital partnership breadth. Scenario models quantify how opioid prescribing regulation and hospital budget constraints move both demand and realizable pricing. The report includes delivered-cost modeling by procedure category and a manufacturer formulary-readiness screen built for hospital pain management and pharmacy procurement teams.
Formulary cost-curve modeling across major procedure categories
Opioid prescribing regulation tracking and compliance deadline database
Extended-release and device demand forecasts by country
Clinical evidence and training infrastructure benchmarking across manufacturers
Active ingredient sourcing cost exposure modeling by manufacturer scale
Opioid-sparing protocol adoption scenarios under bull and bear cases

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts